She previously was head of US sales at Invitae and a regional manager at GeneDx. MedGenome ... Sheldon is EVP/SVP of Digital Insights at Qiagen, according to his LinkedIn profile, and joined Centogene ...

Let's not forget about Abbott Laboratories' impressive streak of 52 consecutive annual dividend increases, which also makes ...

Piper Sandler initiates coverage on Abbott with an Overweight rating, citing its diversified business model, strong medtech ...

Adam Maeder, an analyst from Piper Sandler, has initiated a new Buy rating on Abbott Laboratories (ABT). Adam Maeder has given his Buy rating ...

Abbott Laboratories' diabetes care segment recently added new products to its lineup. It should remain one of the company's key growth drivers over the long run. There are other good reasons to ...

In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories (ABT – Research Report), ...

The stock's fall snapped a two-day winning streak.

Abbott Laboratories closed $4.01 short of its 52-week high ($121.64), which the company reached on March 8th.

Over the past few years, Abbott Laboratories' (NYSE: ABT) business has been a bit of a roller coaster. The pandemic disrupted its medical device business, but it was later able to smooth out those ...

See our latest analysis for Abbott Laboratories We are going to use a two-stage DCF model, which, as the name states, takes into account two stages of growth. The first stage is generally a higher ...

Fintel reports that on September 19, 2024, Piper Sandler initiated coverage of Abbott Laboratories (NYSE:ABT) with a Overweight recommendation. As of August 26, 2024, the average one-year price ...